Abstract：Objective To investigate the combined use of sintilimab and gemcitabine+cisplatin(GP) regimen chemotherapy in advanced non-small cell lung cancer. Methods 78 patients with advanced NSCLC were categorized into two groups with random numerical table.The patients of control group were administrated GP regimen,and on this basis,the patients of observation group additionally took sintilimab.The comparisons were made on clinical therapeutic effect,tumor growth factors,tumor markers,immune indicators,and adverse reactions in both groups. Results The ORR of the observation group was higher than the control group(P>0.05),while the DCR was higher,with statistical difference(P<0.05); The observation group had lower levels of vascular endothelial growth factor(VEGF),basic fibroblast growth factor(BFGF),carcinoembryonic antigen(CEA),and T cell subset CD8+ and higher CD4+ compared with the control group after treatment(P<0.05); The comparisons of adverse reactions in both groups expressed no statistical difference(P>0.05). Conclusion The combination of sintilimab and GP regimen chemotherapy can reduce serum tumor growth factors and tumor markers in patients with advanced NSCLC,and improve immune indicators,which is safe and controllable.
张月良, 甘惠贞, 林惠娥, 黄虹虹. 信迪利单抗结合GP方案化疗对晚期NSCLC患者血清VEGF、BFGF水平及免疫指标的影响[J]. 哈尔滨医药, 2025, 45(6): 18-20.
Zhang Yueliang, Gan Huizhen, Lin Hui'e, Huang Honghong. The Effect of Sintilimab Combined with GP Regimen Chemotherapy on Serum VEGF,BFGF Levels and Immune Indicators in Advanced NSCLC Patients. journal1, 2025, 45(6): 18-20.
2025, Vol. 45 
